Incorporation of microRNA expression in pharmacogenetic prediction models

将 microRNA 表达纳入药物遗传学预测模型

基本信息

  • 批准号:
    7641876
  • 负责人:
  • 金额:
    $ 20.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-03-01 至 2011-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Most chemotherapeutic drugs affect both tumor and normal cells, are ineffective in a number of patients, and exhibit serious toxicity; hence developing predictive models that identify patients at risk for adverse reactions and/or non-response to chemotherapeutic agents prior to treatment is essential. An objective of this proposal is to take a concerted translational effort to elucidate the underlying cause for the inter-ethnic differences in sensitivity to chemotherapy. In this proposal, we will focus on two classes of cytotoxic agents: platinating agents (cisplatin and carboplatin) and antimetabolites (capecitabine and Ara-C), of which significant inter-ethnic differences in cellular sensitivity have been observed in vitro. Our hypothesis is that there are microRNA (miRNA) expression differences in individuals of African descent compared to individuals of European descent that contribute, at least in part, to the difference in sensitivity to chemotherapy-induced cytotoxicity in these two populations. Our long-term goal is to develop an unbiased genome-wide model to identify germline genetic variants, mRNA or miRNA expression including those in an underserved population, that predict risk for adverse reactions and non-response to chemotherapy. Our hypothesis is that there is a set of germline pharmacogenetic polymorphisms associated with the expression of miRNA that affect chemotherapy-induced cytotoxicity and these polymorphisms exhibit interethnic differences. Our specific aims are 1) To quantify genome-wide miRNA expression in HapMap lymphoblastoid cell lines (LCLs) and to identify SNPs associated with miRNA expression and chemotherapy-induced cytotoxicity; 2) To identify mRNA and miRNA expression signatures that significantly correlate with chemotherapy sensitivity and to compare the miRNA expression chemotherapeutic sensitivity signatures in different ethnic populations; 3) To replicate our findings in additional LCLs. PUBLIC HEALTH RELEVANCE: This proposal is intended to better understand how genetic variation contributes to individual sensitivity to chemotherapy. The long term goal is to identify patients, using their genetic make up, that are at risk for toxicities associated with chemotherapy with the intent to reduce their chances of an adverse event.
描述(由申请人提供):大多数化疗药物影响肿瘤和正常细胞,在许多患者中无效,并表现出严重的毒性;因此,开发预测模型,在治疗前识别具有不良反应和/或对化疗药物无反应风险的患者是至关重要的。本提案的目的是采取协调一致的翻译努力,阐明种族间化疗敏感性差异的根本原因。在本提案中,我们将重点关注两类细胞毒性药物:铂类药物(顺铂和卡铂)和抗代谢药物(卡培他滨和阿糖胞苷),其中已在体外观察到细胞敏感性的显著种族间差异。我们的假设是,非洲裔个体与欧洲裔个体相比,存在微小RNA(miRNA)表达差异,这至少部分导致了这两个人群对化疗诱导的细胞毒性的敏感性差异。我们的长期目标是开发一个无偏见的全基因组模型,以识别生殖系遗传变异,mRNA或miRNA表达,包括那些在服务不足的人群中,预测不良反应和化疗无反应的风险。我们的假设是,存在一组与影响化疗诱导的细胞毒性的miRNA表达相关的生殖系药物遗传学多态性,并且这些多态性表现出种族间差异。我们的具体目标是:1)定量HapMap淋巴母细胞样细胞系(LCL)中全基因组miRNA的表达,并鉴定与miRNA表达和化疗诱导的细胞毒性相关的SNP; 2)鉴定与化疗敏感性显著相关的mRNA和miRNA表达特征,并比较不同种族人群中miRNA表达化疗敏感性特征; 3)在其他LCL中复制我们的发现。公共卫生相关性:该提案旨在更好地了解遗传变异如何影响个体对化疗的敏感性。长期目标是利用患者的遗传组成来识别具有与化疗相关的毒性风险的患者,以降低其发生不良事件的机会。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mary Eileen Dolan其他文献

Mary Eileen Dolan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mary Eileen Dolan', 18)}}的其他基金

Chicago EYES (Educators and Youth Enjoy Science) on Cancer
芝加哥之眼(教育工作者和青少年享受科学)关注癌症
  • 批准号:
    9769677
  • 财政年份:
    2017
  • 资助金额:
    $ 20.59万
  • 项目类别:
Chicago EYES (Educators and Youth Enjoy Science) on Cancer
芝加哥之眼(教育工作者和青少年享受科学)关注癌症
  • 批准号:
    10929574
  • 财政年份:
    2017
  • 资助金额:
    $ 20.59万
  • 项目类别:
Chicago EYES (Educators and Youth Enjoy Science) on Cancer
芝加哥之眼(教育工作者和青少年享受科学)关注癌症
  • 批准号:
    10001463
  • 财政年份:
    2017
  • 资助金额:
    $ 20.59万
  • 项目类别:
Chicago EYES (Educators and Youth Enjoy Science) on Cancer
芝加哥之眼(教育工作者和青少年享受科学)关注癌症
  • 批准号:
    10471770
  • 财政年份:
    2017
  • 资助金额:
    $ 20.59万
  • 项目类别:
Epigenetic and Genetic Dissection of Drug Response
药物反应的表观遗传学和遗传学剖析
  • 批准号:
    8309059
  • 财政年份:
    2011
  • 资助金额:
    $ 20.59万
  • 项目类别:
Epigenetic and Genetic Dissection of Drug Response
药物反应的表观遗传学和遗传学剖析
  • 批准号:
    8178832
  • 财政年份:
    2011
  • 资助金额:
    $ 20.59万
  • 项目类别:
CORE III - Lymphoblastoid Cell Line CORE (LCL)
CORE III - 类淋巴母细胞系 CORE (LCL)
  • 批准号:
    8153263
  • 财政年份:
    2010
  • 资助金额:
    $ 20.59万
  • 项目类别:
Genetic determinants associated with pemetrexed response and toxicity
与培美曲塞反应和毒性相关的遗传决定因素
  • 批准号:
    8096819
  • 财政年份:
    2009
  • 资助金额:
    $ 20.59万
  • 项目类别:
Genetic determinants associated with pemetrexed response and toxicity
与培美曲塞反应和毒性相关的遗传决定因素
  • 批准号:
    7742080
  • 财政年份:
    2009
  • 资助金额:
    $ 20.59万
  • 项目类别:
Genetic determinants associated with pemetrexed response and toxicity
与培美曲塞反应和毒性相关的遗传决定因素
  • 批准号:
    8469831
  • 财政年份:
    2009
  • 资助金额:
    $ 20.59万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 20.59万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 20.59万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 20.59万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 20.59万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 20.59万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 20.59万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 20.59万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 20.59万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 20.59万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 20.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了